Something is bugging me this week. Okay, lots of things are bugging me this week, but the one that is relevant to this newsletter is the STAT News headline that implied it is awesome to be a pharmaceutical executive in 2026. This week, there were reports of more than 25,000 layoffs in pharma last year. And then there is the uncertainty of what the White House might ask for next. Yes, that is what the money is for, but life in the pharma lane feels wobbly. Uncertainty might be the word for 2026.

If you checked out over the last few weeks, I hope this helps catch you up. Re-entry took a few days, but I’m back in the saddle and ready for what lies ahead. I think.

Hold, Please. On December 29, the U.S. District Court for the District of Maine issued a  preliminary injunction that halted the Health Resources and Services Administration (HRSA) 340B Drug Pricing Program (340B) Rebate Model Pilot Program. Nine manufacturers received approval covering ten drugs, and the pilot was slated to start on January 1, 2026, which explains the flurry of end-of-year contingency planning on both the provider and manufacturer sides.

The court said the government failed to grapple with covered entities’ reliance on point-of-sale discounts and did not adequately consider administrative and working capital costs. On December 31, the First Circuit denied an administrative stay. On January 7, the First Circuit denied the broader stay request, keeping the injunction in place. HRSA paused implementation on December 31.

The operational issue is working capital. A rebate construct requires safety-net providers to float wholesale acquisition cost (WAC) amounts and then wait for repayments. The district court noted evidence that many hospitals operate with very limited days cash on hand, so shifting the timing of cash flows would force cuts to services and staffing, not just create back-office headaches. Clears throat. This is happening against a backdrop of continued program growth. HRSA reports 340B covered entities purchased $81.4 billion in drugs in 2024, a jump that keeps political attention fixed on program size and oversight. For now, we wait for next steps.

Deal or No Deal. On December 19, President Trump packed the Roosevelt Room with nine pharmaceutical executives and declared “the largest developments to date” in bringing most-favored-nation (MFN) pricing to American patients. The White House announced new agreements with Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi, on top of earlier deals with Pfizer, AstraZeneca, Lilly, Novo Nordisk, and EMD Serono.

The headline pledge is alignment of many Medicaid prices and future launches with the lowest prices paid in other wealthy countries. Some products will also be sold directly to patients through the new TrumpRx.gov platform at steep discounts, including examples like Gilead’s Epclusa at a reported 90 percent cut and Merck’s diabetes drugs with discounts up to 70 percent. Bristol Myers Squibb committed to providing Eliquis free for Medicaid.

In return, companies receive three years of protection from threatened Section 232 tariffs and a public signal that the administration prefers negotiated deals to new statute. While the deals reached with the administration are not public, it is widely believed that they exempt these companies from MFN proposals or demonstrations that the administration might introduce, such as the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model, the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model, or the Global Benchmark for Efficient Drug Pricing (GLOBE) Model.

Drug policy in Trump’s second term is starting to look less like a coherent framework and more like a portfolio of deals. On one side sit voluntary MFN agreements; on the other are Section 1115A models that hardwire MFN logic into Medicaid and Medicare.

GENEROUS would peg Medicaid net costs for selected drugs to MFN prices through supplemental rebates, combined with standardized coverage criteria across participating states. GUARD and GLOBE would do similar work in Medicare Part D (Part D) and Medicare Part B (Part B), using international reference prices to calculate rebates when U.S. spending exceeds benchmarks. BALANCE layers GLP-1 coverage and lifestyle support on top of those price signals.  (Summary of BALANCE is below and GUARD summary is here.)

The common thread is governance by contract, not comprehensive legislation. Terms vary by manufacturer, product, and model. Details are unevenly transparent, and durability depends on future administrations choosing to honor or unwind “voluntary” arrangements.

For manufacturers, the upside is the chance to shape terms up front and avoid more rigid statutory controls. The downside is navigating overlapping deal regimes that may conflict with one another and with pricing strategies outside the United States. For advocates and payers, the open question is whether a deals-based system can deliver sustained affordability, or whether it mainly shifts who gets the best contract at any given moment.

Side note: during the press conference, President Trump said he just realized that health plans should be doing more and implied they would be next in terms of deals.

Trust but Verify. In December, ProPublica  reported that the Food and Drug Administration (FDA) does not routinely test generic drugs to confirm quality and performance, even though generics make up the bulk of U.S. prescriptions. Instead, the agency relies heavily on manufacturer testing and a targeted, risk-based approach to surveillance.

ProPublica commissioned an independent lab to test three widely used medicines: bupropion XL (generic Wellbutrin XL), metoprolol succinate (generic Toprol XL), and atorvastatin (generic Lipitor). Most samples passed, but the investigation reported that some versions dissolved more slowly than brand-name products, which experts said could matter clinically depending on the drug and the patient.

The policy relevance is bigger than a single lab test. Generic confidence is the foundation of affordability strategy, and supply chains are global. ProPublica also highlighted inspection and oversight challenges, including limitations on what patients and clinicians can learn about where a specific generic was made. The story lands at an awkward intersection: the system leans on generics for savings, but the oversight narrative is mostly trust-based and opaque.

For manufacturers and advocates, this is a reminder that “generic equals equivalent” is not just a clinical claim. It is a governance promise. When post-market testing is limited, quality failures become harder to detect early, and the reputational blast radius can hit the entire generic market, not just one manufacturer.

Ball Dropped, and So Did Prices. On January 1, Medicare’s first negotiated Maximum Fair Prices (MFPs) took effect for ten Medicare Part D drugs, moving the Inflation Reduction Act (IRA) negotiation program from policy to point-of-sale operations. The Centers for Medicare & Medicaid Services (CMS) has been clear that these MFPs apply beginning January 1, 2026.

The less visible story is the plumbing. CMS built a Medicare Transaction Facilitator to support MFP effectuation, including the data flows that enable dispensing entities to receive manufacturer refund payments tied to eligible claims.

This is where “how is it going at the counter” can miss the main risk. Beneficiary cost-sharing still depends on plan design, but pharmacy financial exposure can hinge on the timing and accuracy of refunds and reconciliation. The early success metric is not just whether prices dropped; it is whether claims adjudicate cleanly, refund workflows are predictable, and pharmacies feel confident dispensing without fearing delayed make-whole payments. Negotiation is now a systems test, not a press release.

Policy Fundamentals: GLP-1s in BALANCE

In December, CMS rolled out one of the most ambitious obesity coverage experiments federal programs have tried so far. The Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model is a voluntary test that lets CMS negotiate directly with manufacturers of select GLP-1 (glucagon-like peptide-1) and related products, then offer those terms to state Medicaid agencies and Medicare Part D plans. The aim is simple and disruptive at the same time: expand access to GLP-1s and lifestyle support for people with Medicare and Medicaid while trying to keep program spending in check.

Under BALANCE, CMS negotiates lower net prices and standardized coverage terms with manufacturers. Negotiation topics include guaranteed net pricing, limits on out-of-pocket costs for beneficiaries, clinical eligibility and prior authorization rules, and the design of evidence-based lifestyle support programs. States and plans that opt in agree to cover the negotiated drugs on those terms. Participation is voluntary for manufacturers, Medicaid programs, and Part D sponsors, which means uptake will not be uniform across the country.

BALANCE also crosses a long-standing line. Medicare law excludes drugs “when used for weight loss.” Through CMS Innovation Center authority (the Center for Medicare and Medicaid Innovation, CMMI), CMS is testing Part D coverage of those same products when they are paired with negotiated prices and structured lifestyle interventions. In practice, this is a five-year trial of whether that exclusion can be softened without new legislation.

How BALANCE Is Supposed to Work

The model focuses on GLP-1 and related drugs with weight management indications and at least ten percent average weight loss in clinical trials. CMS sets product-level terms that include lower net prices, a cap on cost-sharing within the basic Part D benefit, and standardized coverage criteria. States participating through Medicaid use supplemental rebates and the same common criteria to operationalize the deal.

Everyone who receives a model drug for weight management is also supposed to have access to a lifestyle program, delivered by or on behalf of the manufacturer at no cost to the beneficiary. CMS describes this as education and support on diet, physical activity, and maintaining weight loss, consistent with FDA labeling that expects GLP-1s to be combined with lifestyle change.

The model runs through December 2031, with Medicaid coverage starting as early as May 2026 and Part D coverage beginning in January 2027.

2026 Part D Bridge

BALANCE does not start in Part D until 2027, but CMS is not waiting that long to move members. A separate Medicare GLP-1 payment demonstration is scheduled to begin in July 2026. During this six-month bridge, qualifying beneficiaries would be able to access GLP-1s at prices negotiated by the administration, paying a flat $50 per month. The demonstration sits outside the normal Part D benefit, and plans do not carry risk for the drugs furnished under it.

The bridge will test operational details such as eligibility verification, pharmacy workflows, and communication with beneficiaries before plans and states must commit to full BALANCE participation in 2027.

Who Participates and Who Is Left Out

Eligible manufacturers include those already marketing or expecting to market a GLP-1, glucose-dependent insulinotropic polypeptide (GIP), or related product with a weight management indication by early 2027. Participating states must be in the Medicaid Drug Rebate Program. Part D sponsors, including standalone prescription drug plans and Medicare Advantage prescription drug plans, can join through a notice of intent process. Initial applications and notices were due on January 8, 2026.

Because participation is voluntary, coverage will depend on which manufacturers sign up and which states and plans follow. Early commentary from patient advocates and obesity groups has already flagged that beneficiaries will not know, at least initially, whether their state or plan participates, and there is no guarantee any particular individual will meet the negotiated eligibility criteria.

Open Questions

Several critical design elements are still open, and they will determine whether BALANCE is a meaningful access expansion or a niche experiment.

• Clinical criteria. CMS has not finalized the exact eligibility rules. Body mass index (BMI) thresholds, comorbid conditions, and required documentation will decide who gets through the door and who does not.
• Prior authorization and continuity. There is little detail on how often beneficiaries will need to requalify, how renewals will be handled, and what protections exist for people who switch plans or have temporary gaps in coverage.
• Lifestyle programs. The type, intensity, and accessibility of lifestyle support is not defined in detail. It is not yet clear whether programs will be consistent across manufacturers, available in multiple languages, or useable for people without reliable internet access.
• Transparency. There is no simple mechanism today for a beneficiary to see, during plan selection, whether a plan participates in BALANCE, which drugs it covers, and what the negotiated cost sharing looks like over a full year of treatment.

Beyond those mechanics, BALANCE sits inside a crowded policy neighborhood. It overlaps with Trump MFN-style deals for GLP-1s, with the GUARD and GLOBE international reference pricing models, and with the GENEROUS Medicaid model that also uses most-favored-nation logic. How all those interact is still unclear.

Why BALANCE Matters

BALANCE is more than another Innovation Center model. It is a test case for whether federal programs can treat obesity and metabolic disease as prevention targets, using a mix of price negotiation, standardized access rules, and embedded support services. If it works, the structure could be reused for other high-cost prevention therapies that live on the edge of traditional benefit categories.

For manufacturers, BALANCE represents both a risk and an opportunity: clearer, potentially broader coverage in exchange for lower net prices and tighter, public parameters around who is treated and how. For states and plans, it is a chance to buy down uncertainty in a therapeutic area where unmet demand is high, and budget exposure is very real.

The open question is whether the promise of negotiated GLP-1 access and lifestyle support can survive real-world implementation, with all the variability and friction that implies. That is what 2026 and 2027 will reveal.